Smart Drug Delivery Systems Market (Product: Connected Inhalers, Connected Autoinjectors, Connected Pen injectors, Connected Wearable Injectors, Add-on Sensors, & Others) - Global Industry Analysis, Size, Share, Growth, Trends, & Forecast, 2022-2031

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Smart Drug Delivery Systems Market

4. Market Overview

• 4.1. Overview
• 4.2. Market Dynamics
  • 4.2.1. Drivers
  • 4.2.2. Restraints
  • 4.2.3. Opportunities

5. Key Insights

• 5.1. Smart Insulin Pen - Brand Analysis
• 5.2. Insulin Pen Delivery Devices Available in the U.S.
• 5.3. Insights on Digitization of Diabetes: Opportunities & Challenges
• 5.4. Key Industry Events (Partnership, Merger & Acquisition, etc.)
• 5.5. COVID-19 Impact Analysis

6. Global Smart Drug Delivery Systems Market Analysis and Forecast, by Product

• 6.1. Introduction & Definition
• 6.2. Key Findings/Developments
• 6.3. Market Value Forecast, by Product, 2017-2031
  • 6.3.1. Connected Inhalers
  • 6.3.2. Connected Autoinjectors
  • 6.3.3. Connected Pen Injectors
  • 6.3.4. Connected Wearable Injectors
  • 6.3.5. Add-on Sensors
  • 6.3.6. Others
• 6.4. Market Attractiveness Analysis, by Product

7. Global Smart Drug Delivery Systems Market Analysis and Forecast, by Drug Delivery Mode

• 7.1. Introduction & Definition
• 7.2. Key Findings/Developments
• 7.3. Market Value Forecast, by Drug Delivery Mode, 2017-2031
  • 7.3.1. Injectable
  • 7.3.2. Inhalation
  • 7.3.3. Oral
• 7.4. Market Attractiveness Analysis, by Drug Delivery Mode

8. Global Smart Drug Delivery Systems Market Analysis and Forecast, by Therapeutic Area

• 8.1. Introduction & Definition
• 8.2. Key Findings/Developments
• 8.3. Market Value Forecast, by Therapeutic Area, 2017-2031
  • 8.3.1. Metabolic Disorders
  • 8.3.2. Neurological Disorders
  • 8.3.3. Respiratory Disorders
  • 8.3.4. Hormonal Disorders
  • 8.3.5. Others
• 8.4. Market Attractiveness Analysis, by Therapeutic Area

9. Global Smart Drug Delivery Systems Market Analysis and Forecast, by End-user

• 9.1. Introduction & Definition
• 9.2. Key Findings/Developments
• 9.3. Market Value Forecast, by End-user, 2017-2031
  • 9.3.1. Hospitals
  • 9.3.2. Clinics
  • 9.3.3. Home Care
  • 9.3.4. Ambulatory Care Settings
  • 9.3.5. Others
• 9.4. Market Attractiveness Analysis, by End-user

10. Global Smart Drug Delivery Systems Market Analysis and Forecast, by Region

• 10.1. Key Findings
• 10.2. Market Value Forecast, by Region, 2017-2031
  • 10.2.1. North America
  • 10.2.2. Europe
  • 10.2.3. Asia Pacific
  • 10.2.4. Latin America
  • 10.2.5. Middle East & Africa
• 10.3. Market Attractiveness By Country/Region

11. North America Smart Drug Delivery Systems Market Analysis and Forecast

• 11.1. Introduction
  • 11.1.1. Key Findings
• 11.2. Market Value Forecast, by Product, 2017-2031
  • 11.2.1. Connected Inhalers
  • 11.2.2. Connected Autoinjectors
  • 11.2.3. Connected Pen Injectors
  • 11.2.4. Connected Wearable Injectors
  • 11.2.5. Add-on Sensors
  • 11.2.6. Others
• 11.3. Market Value Forecast, by Drug Delivery Mode, 2017-2031
  • 11.3.1. Injectable
  • 11.3.2. Inhalation
  • 11.3.3. Oral
• 11.4. Market Value Forecast, by Therapeutic Area, 2017-2031
  • 11.4.1. Metabolic Disorders
  • 11.4.2. Neurological Disorders
  • 11.4.3. Respiratory Disorders
  • 11.4.4. Hormonal Disorders
  • 11.4.5. Others
• 11.5. Market Value Forecast, by End-user, 2017-2031
  • 11.5.1. Hospitals
  • 11.5.2. Clinics
  • 11.5.3. Home Care
  • 11.5.4. Ambulatory Care Settings
  • 11.5.5. Others
• 11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 11.6.1. U.S.
  • 11.6.2. Canada
• 11.7. Market Attractiveness Analysis
  • 11.7.1. By Product
  • 11.7.2. By Drug Delivery Mode
  • 11.7.3. By Therapeutic Area
  • 11.7.4. By End-user
  • 11.7.5. By Country/Sub-region

12. Europe Smart Drug Delivery Systems Market Analysis and Forecast

• 12.1. Introduction
  • 12.1.1. Key Findings
• 12.2. Market Value Forecast, by Product, 2017-2031
  • 12.2.1. Connected Inhalers
  • 12.2.2. Connected Autoinjectors
  • 12.2.3. Connected Pen Injectors
  • 12.2.4. Connected Wearable Injectors
  • 12.2.5. Add-on Sensors
  • 12.2.6. Others
• 12.3. Market Value Forecast, by Drug Delivery Mode, 2017-2031
  • 12.3.1. Injectable
  • 12.3.2. Inhalation
  • 12.3.3. Oral
• 12.4. Market Value Forecast, by Therapeutic Area, 2017-2031
  • 12.4.1. Metabolic Disorders
  • 12.4.2. Neurological Disorders
  • 12.4.3. Respiratory Disorders
  • 12.4.4. Hormonal Disorders
  • 12.4.5. Others
• 12.5. Market Value Forecast, by End-user, 2017-2031
  • 12.5.1. Hospitals
  • 12.5.2. Clinics
  • 12.5.3. Home Care
  • 12.5.4. Ambulatory Care Settings
  • 12.5.5. Others
• 12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 12.6.1. Germany
  • 12.6.2. U.K.
  • 12.6.3. France
  • 12.6.4. Italy
  • 12.6.5. Spain
  • 12.6.6. Rest of Europe
• 12.7. Market Attractiveness Analysis
  • 12.7.1. By Product
  • 12.7.2. By Drug Delivery Mode
  • 12.7.3. By Therapeutic Area
  • 12.7.4. By End-user
  • 12.7.5. By Country/Sub-region

13. Asia Pacific Smart Drug Delivery Systems Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast, by Product, 2017-2031
  • 13.2.1. Connected Inhalers
  • 13.2.2. Connected Autoinjectors
  • 13.2.3. Connected Pen Injectors
  • 13.2.4. Connected Wearable Injectors
  • 13.2.5. Add-on Sensors
  • 13.2.6. Others
• 13.3. Market Value Forecast, by Drug Delivery Mode, 2017-2031
  • 13.3.1. Injectable
  • 13.3.2. Inhalation
  • 13.3.3. Oral
• 13.4. Market Value Forecast, by Therapeutic Area, 2017-2031
  • 13.4.1. Metabolic Disorders
  • 13.4.2. Neurological Disorders
  • 13.4.3. Respiratory Disorders
  • 13.4.4. Hormonal Disorders
  • 13.4.5. Others
• 13.5. Market Value Forecast, by End-user, 2017-2031
  • 13.5.1. Hospitals
  • 13.5.2. Clinics
  • 13.5.3. Home Care
  • 13.5.4. Ambulatory Care Settings
  • 13.5.5. Others
• 13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 13.6.1. China
  • 13.6.2. Japan
  • 13.6.3. India
  • 13.6.4. Australia & New Zealand
  • 13.6.5. Rest of Asia Pacific
• 13.7. Market Attractiveness Analysis
  • 13.7.1. By Product
  • 13.7.2. By Drug Delivery Mode
  • 13.7.3. By Therapeutic Area
  • 13.7.4. By End-user
  • 13.7.5. By Country/Sub-region

14. Latin America Smart Drug Delivery Systems Market Analysis and Forecast

• 14.1. Introduction
  • 14.1.1. Key Findings
• 14.2. Market Value Forecast, by Product, 2017-2031
  • 14.2.1. Connected Inhalers
  • 14.2.2. Connected Autoinjectors
  • 14.2.3. Connected Pen Injectors
  • 14.2.4. Connected Wearable Injectors
  • 14.2.5. Add-on Sensors
  • 14.2.6. Others
• 14.3. Market Value Forecast, by Drug Delivery Mode, 2017-2031
  • 14.3.1. Injectable
  • 14.3.2. Inhalation
  • 14.3.3. Oral
• 14.4. Market Value Forecast, by Therapeutic Area, 2017-2031
  • 14.4.1. Metabolic Disorders
  • 14.4.2. Neurological Disorders
  • 14.4.3. Respiratory Disorders
  • 14.4.4. Hormonal Disorders
  • 14.4.5. Others
• 14.5. Market Value Forecast, by End-user, 2017-2031
  • 14.5.1. Hospitals
  • 14.5.2. Clinics
  • 14.5.3. Home Care
  • 14.5.4. Ambulatory Care Settings
  • 14.5.5. Others
• 14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 14.6.1. Brazil
  • 14.6.2. Mexico
  • 14.6.3. Rest of Latin America
• 14.7. Market Attractiveness Analysis
  • 14.7.1. By Product
  • 14.7.2. By Drug Delivery Mode
  • 14.7.3. By Therapeutic Area
  • 14.7.4. By End-user
  • 14.7.5. By Country/Sub-region

15. Middle East & Africa Smart Drug Delivery Systems Market Analysis and Forecast

• 15.1. Introduction
  • 15.1.1. Key Findings
• 15.2. Market Value Forecast, by Product, 2017-2031
  • 15.2.1. Connected Inhalers
  • 15.2.2. Connected Autoinjectors
  • 15.2.3. Connected Pen Injectors
  • 15.2.4. Connected Wearable Injectors
  • 15.2.5. Add-on Sensors
  • 15.2.6. Others
• 15.3. Market Value Forecast, by Drug Delivery Mode, 2017-2031
  • 15.3.1. Injectable
  • 15.3.2. Inhalation
  • 15.3.3. Oral
• 15.4. Market Value Forecast, by Therapeutic Area, 2017-2031
  • 15.4.1. Metabolic Disorders
  • 15.4.2. Neurological Disorders
  • 15.4.3. Respiratory Disorders
  • 15.4.4. Hormonal Disorders
  • 15.4.5. Others
• 15.5. Market Value Forecast, by End-user, 2017-2031
  • 15.5.1. Hospitals
  • 15.5.2. Clinics
  • 15.5.3. Home Care
  • 15.5.4. Ambulatory Care Settings
  • 15.5.5. Others
• 15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 15.6.1. GCC Countries
  • 15.6.2. South Africa
  • 15.6.3. Rest of Middle East & Africa
• 15.7. Market Attractiveness Analysis
  • 15.7.1. By Product
  • 15.7.2. By Drug Delivery Mode
  • 15.7.3. By Therapeutic Area
  • 15.7.4. By End-user
  • 15.7.5. By Country/Sub-region

16. Competition Landscape

• 16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
• 16.2. Market Share Analysis, by Company (2021)
• 16.3. Company Profiles
  • 16.3.1. Abbott Laboratories
    • 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.1.2. Product Portfolio
    • 16.3.1.3. Financial Overview
    • 16.3.1.4. Strategic Overview
    • 16.3.1.5. SWOT Analysis
  • 16.3.2. Adherium Ltd.
    • 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.2.2. Product Portfolio
    • 16.3.2.3. Financial Overview
    • 16.3.2.4. Strategic Overview
    • 16.3.2.5. SWOT Analysis
  • 16.3.3. Amiko Digital Health Limited
    • 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.3.2. Product Portfolio
    • 16.3.3.3. Financial Overview
    • 16.3.3.4. Strategic Overview
    • 16.3.3.5. SWOT Analysis
  • 16.3.4. Becton, Dickinson and Company
    • 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.4.2. Product Portfolio
    • 16.3.4.3. Financial Overview
    • 16.3.4.4. Strategic Overview
    • 16.3.4.5. SWOT Analysis
  • 16.3.5. BIOCORP
    • 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.5.2. Product Portfolio
    • 16.3.5.3. Financial Overview
    • 16.3.5.4. Strategic Overview
    • 16.3.5.5. SWOT Analysis
  • 16.3.6. CeQur Corporation
    • 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.6.2. Product Portfolio
    • 16.3.6.3. Financial Overview
    • 16.3.6.4. Strategic Overview
    • 16.3.6.5. SWOT Analysis
  • 16.3.7. Cognita Labs
    • 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.7.2. Product Portfolio
    • 16.3.7.3. Financial Overview
    • 16.3.7.4. Strategic Overview
    • 16.3.7.5. SWOT Analysis
  • 16.3.8. E3D Elcam Drug Delivery Devices
    • 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.8.2. Product Portfolio
    • 16.3.8.3. Financial Overview
    • 16.3.8.4. Strategic Overview
    • 16.3.8.5. SWOT Analysis
  • 16.3.9. H&T Presspart Manufacturing Ltd.
    • 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.9.2. Product Portfolio
    • 16.3.9.3. Financial Overview
    • 16.3.9.4. Strategic Overview
    • 16.3.9.5. SWOT Analysis
  • 16.3.10. HCmed Innovations Co., Ltd.
    • 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.10.2. Product Portfolio
    • 16.3.10.3. Financial Overview
    • 16.3.10.4. Strategic Overview
    • 16.3.10.5. SWOT Analysis
  • 16.3.11. Medtronic plc
    • 16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.11.2. Product Portfolio
    • 16.3.11.3. Financial Overview
    • 16.3.11.4. Strategic Overview
    • 16.3.11.5. SWOT Analysis
  • 16.3.12. Novo Nordisk
    • 16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.12.2. Product Portfolio
    • 16.3.12.3. Financial Overview
    • 16.3.12.4. Strategic Overview
    • 16.3.12.5. SWOT Analysis
  • 16.3.13. Phillips-Medisize
    • 16.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.13.2. Product Portfolio
    • 16.3.13.3. Financial Overview
    • 16.3.13.4. Strategic Overview
    • 16.3.13.5. SWOT Analysis
  • 16.3.14. Sonceboz
    • 16.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.14.2. Product Portfolio
    • 16.3.14.3. Financial Overview
    • 16.3.14.4. Strategic Overview
    • 16.3.14.5. SWOT Analysis

List of Tables

• Table 01: Smart Insulin Pen - Brand Analysis
• Table 02: Insulin Pen Delivery Devices Available in the United States
• Table 03: Global Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Product, 2017-2031
• Table 04: Global Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Drug Delivery Mode, 2017-2031
• Table 05: Global Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017-2031
• Table 06: Global Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by End-user, 2017-2031
• Table 07: Global Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Region, 2017-2031
• Table 08: North America Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Product, 2017-2031
• Table 09: North America Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Drug Delivery Mode, 2017-2031
• Table 10: North America Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017-2031
• Table 11: North America Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by End-user, 2017-2031
• Table 12: North America Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Country, 2017-2031
• Table 13: Europe Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Product, 2017-2031
• Table 14: Europe Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Drug Delivery Mode, 2017-2031
• Table 15: Europe Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017-2031
• Table 16: Europe Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by End-user, 2017-2031
• Table 17: Europe Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
• Table 18: Asia Pacific Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Product, 2017-2031
• Table 19: Asia Pacific Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Drug Delivery Mode, 2017-2031
• Table 20: Asia Pacific Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017-2031
• Table 21: Asia Pacific Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by End-user, 2017-2031
• Table 22: Asia Pacific Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
• Table 23: Latin America Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Product, 2017-2031
• Table 24: Latin America Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Drug Delivery Mode, 2017-2031
• Table 25: Latin America Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017-2031
• Table 26: Latin America Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by End-user, 2017-2031
• Table 27: Latin America Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
• Table 28: Middle East & Africa Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Product, 2017-2031
• Table 29: Middle East & Africa Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Drug Delivery Mode, 2017-2031
• Table 30: Middle East & Africa Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017-2031
• Table 31: Middle East & Africa Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by End-user, 2017-2031
• Table 32: Middle East & Africa Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

List of Figures

• Figure 01: Global Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, 2017-2031
• Figure 02: Global Smart Drug Delivery Systems Market Analysis and Forecast, by Product, 2021 and 2031
• Figure 03: Global Smart Drug Delivery Systems Market Attractiveness Analysis, by Product, 2022-2031
• Figure 04: Global Smart Drug Delivery Systems Market (US$ Mn), by Connected Inhalers, 2017-2031
• Figure 05: Global Smart Drug Delivery Systems Market (US$ Mn), by Connected Autoinjectors, 2017-2031
• Figure 06: Global Smart Drug Delivery Systems Market (US$ Mn), by Connected Pen Injectors, 2017-2031
• Figure 07: Global Smart Drug Delivery Systems Market (US$ Mn), by Connected Wearable Injectors, 2017-2031
• Figure 08: Global Smart Drug Delivery Systems Market (US$ Mn), by Add-on Sensors, 2017-2031
• Figure 09: Global Smart Drug Delivery Systems Market (US$ Mn), by Others, 2017-2031
• Figure 10: Global Smart Drug Delivery Systems Market Analysis and Forecast, by Drug Delivery Mode 2021 and 2031
• Figure 11: Global Smart Drug Delivery Systems Market Attractiveness Analysis, by Drug Delivery Mode, 2022-2031
• Figure 12: Global Smart Drug Delivery Systems Market (US$ Mn), by Injectable, 2017-2031
• Figure 13: Global Smart Drug Delivery Systems Market (US$ Mn), by Inhalation, 2017-2031
• Figure 14: Global Smart Drug Delivery Systems Market (US$ Mn), by Oral, 2017-2031
• Figure 15: Global Smart Drug Delivery Systems Market Analysis and Forecast, by Therapeutic Area, 2021 and 2031
• Figure 16: Global Smart Drug Delivery Systems Market Attractiveness Analysis, by Therapeutic Area, 2022-2031
• Figure 17: Global Smart Drug Delivery Systems Market (US$ Mn), by Metabolic Disorders, 2017-2031
• Figure 18: Global Smart Drug Delivery Systems Market (US$ Mn), by Neurological Disorders, 2017-2031
• Figure 19: Global Smart Drug Delivery Systems Market (US$ Mn), by Respiratory Disorders, 2017-2031
• Figure 20: Global Smart Drug Delivery Systems Market (US$ Mn), by Hormonal Disorders, 2017-2031
• Figure 21: Global Smart Drug Delivery Systems Market (US$ Mn), by Others, 2017-2031
• Figure 22: Global Smart Drug Delivery Systems Market Analysis and Forecast, by End-user, 2021 and 2031
• Figure 23: Global Smart Drug Delivery Systems Market Attractiveness Analysis, by End-user, 2022-2031
• Figure 24: Global Smart Drug Delivery Systems Market (US$ Mn), by Hospitals, 2017-2031
• Figure 25: Global Smart Drug Delivery Systems Market (US$ Mn), by Clinics, 2017-2031
• Figure 26: Global Smart Drug Delivery Systems Market (US$ Mn), by Home Care, 2017-2031
• Figure 27: Global Smart Drug Delivery Systems Market (US$ Mn), by Ambulatory Care Settings, 2017-2031
• Figure 28: Global Smart Drug Delivery Systems Market (US$ Mn), by Others, 2017-2031
• Figure 29: Global Smart Drug Delivery Systems Market Analysis and Forecast, by Region, 2021 and 2031
• Figure 30: Global Smart Drug Delivery Systems Market Attractiveness Analysis, by Region, 2022-2031
• Figure 31: North America Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, 2017-2031
• Figure 32: North America Smart Drug Delivery Systems Market Analysis and Forecast, by Product, 2021 and 2031
• Figure 33: North America Smart Drug Delivery Systems Market Attractiveness Analysis, by Product, 2022-2031
• Figure 34: North America Smart Drug Delivery Systems Market Analysis and Forecast, by Drug Delivery Mode, 2021 and 2031
• Figure 35: North America Smart Drug Delivery Systems Market Attractiveness Analysis, by Drug Delivery Mode, 2022-2031
• Figure 36: North America Smart Drug Delivery Systems Market Analysis and Forecast, by Therapeutic Area, 2021 and 2031
• Figure 37: North America Smart Drug Delivery Systems Market Attractiveness Analysis, by Therapeutic Area, 2022-2031
• Figure 38: North America Smart Drug Delivery Systems Market Analysis and Forecast, by End-user, 2021 and 2031
• Figure 39: North America Smart Drug Delivery Systems Market Attractiveness Analysis, by End-user, 2022-2031
• Figure 40: North America Smart Drug Delivery Systems Market Analysis and Forecast, by Country, 2021 and 2031
• Figure 41: North America Smart Drug Delivery Systems Market Attractiveness Analysis, by Country, 2022-2031
• Figure 42: Europe Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, 2017-2031
• Figure 43: Europe Smart Drug Delivery Systems Market Analysis and Forecast, by Product, 2021 and 2031
• Figure 44: Europe Smart Drug Delivery Systems Market Attractiveness Analysis, by Product, 2022-2031
• Figure 45: Europe Smart Drug Delivery Systems Market Analysis and Forecast, by Drug Delivery Mode. 2021 and 2031
• Figure 46: Europe Smart Drug Delivery Systems Market Attractiveness Analysis, by Drug Delivery Mode, 2022-2031
• Figure 47: Europe Smart Drug Delivery Systems Market Analysis and Forecast, by Therapeutic Area, 2021 and 2031
• Figure 48: Europe Smart Drug Delivery Systems Market Attractiveness Analysis, by Therapeutic Area, 2022-2031
• Figure 49: Europe Smart Drug Delivery Systems Market Analysis and Forecast, by End-user, 2021 and 2031
• Figure 50: Europe Smart Drug Delivery Systems Market Attractiveness Analysis, by End-user, 2022-2031
• Figure 51: Europe Smart Drug Delivery Systems Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031
• Figure 52: Europe Smart Drug Delivery Systems Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
• Figure 53: Asia Pacific Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, 2017-2031
• Figure 54: Asia Pacific Smart Drug Delivery Systems Market Analysis and Forecast, by Product, 2021 and 2031
• Figure 55: Asia Pacific Smart Drug Delivery Systems Market Attractiveness Analysis, by Product, 2022-2031
• Figure 56: Asia Pacific Smart Drug Delivery Systems Market Analysis and Forecast, by Drug Delivery Mode 2021 and 2031
• Figure 57: Asia Pacific Smart Drug Delivery Systems Market Attractiveness Analysis, by Drug Delivery Mode, 2022-2031
• Figure 58: Asia Pacific Smart Drug Delivery Systems Market Analysis and Forecast, by Therapeutic Area, 2021 and 2031
• Figure 59: Asia Pacific Smart Drug Delivery Systems Market Attractiveness Analysis, by Therapeutic Area, 2022-2031
• Figure 60: Asia Pacific Smart Drug Delivery Systems Market Analysis and Forecast, by End-user, 2021 and 2031
• Figure 61: Asia Pacific Smart Drug Delivery Systems Market Attractiveness Analysis, by End-user, 2022-2031
• Figure 62: Asia Pacific Smart Drug Delivery Systems Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031
• Figure 63: Asia Pacific Smart Drug Delivery Systems Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
• Figure 64: Latin America Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, 2017-2031
• Figure 65: Latin America Smart Drug Delivery Systems Market Analysis and Forecast, by Product, 2021 and 2031
• Figure 66: Latin America Smart Drug Delivery Systems Market Attractiveness Analysis, by Product, 2022-2031
• Figure 67: Latin America Smart Drug Delivery Systems Market Analysis and Forecast, by Drug Delivery Mode, 2021 and 2031
• Figure 68: Latin America Smart Drug Delivery Systems Market Attractiveness Analysis, by Drug Delivery Mode, 2022-2031
• Figure 69: Latin America Smart Drug Delivery Systems Market Analysis and Forecast, by Therapeutic Area, 2021 and 2031
• Figure 70: Latin America Smart Drug Delivery Systems Market Attractiveness Analysis, by Therapeutic Area, 2022-2031
• Figure 71: Latin America Smart Drug Delivery Systems Market Analysis and Forecast, by End-user, 2021 and 2031
• Figure 72: Latin America Smart Drug Delivery Systems Market Attractiveness Analysis, by End-user, 2022-2031
• Figure 73: Latin America Smart Drug Delivery Systems Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031
• Figure 74: Latin America Smart Drug Delivery Systems Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
• Figure 75: Middle East & Africa Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, 2017-2031
• Figure 76: Middle East & Africa Smart Drug Delivery Systems Market Analysis and Forecast, by Product, 2021 and 2031
• Figure 77: Middle East & Africa Smart Drug Delivery Systems Market Attractiveness Analysis, by Product, 2022-2031
• Figure 78: Middle East & Africa Smart Drug Delivery Systems Market Analysis and Forecast, by Drug Delivery Mode, 2021 and 2031
• Figure 79: Middle East & Africa Smart Drug Delivery Systems Market Attractiveness Analysis, by Drug Delivery Mode, 2022-2031
• Figure 80: Middle East & Africa Smart Drug Delivery Systems Market Analysis and Forecast, by Therapeutic Area, 2021 and 2031
• Figure 81: Middle East & Africa Smart Drug Delivery Systems Market Attractiveness Analysis, by Therapeutic Area, 2022-2031
• Figure 82: Middle East & Africa Smart Drug Delivery Systems Market Analysis and Forecast, by End-user, 2021 and 2031
• Figure 83: Middle East & Africa Smart Drug Delivery Systems Market Attractiveness Analysis, by End-user, 2022-2031
• Figure 84: Middle East & Africa Smart Drug Delivery Systems Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031
• Figure 85: Middle East & Africa Smart Drug Delivery Systems Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
• Figure 86: Global Smart Drug Delivery Systems Market Share Analysis/Ranking, by Company, 2021